VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.
Starting soon · Phase 2
Conditions studied: Acute Myeloid Leukemia (AML)
In brief
Objective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML). Key Research Questions: 1. Is the efficacy of the two-week VA-CAG regimen equivalent to that of the three-week regimen in inducing remission in AML? 2. Does the two-week VA-CAG regimen reduce treatment-related adverse events compared to the three-week regimen? Methods: Researchers will compare the efficacy and safety of the two-week VA-CAG regimen with the three-week regimen for induction remission in AML. Study participants will be randomly assigned to receive standard treatment with either the two-week or three-week VA-CAG regimen. Patients are required to attend monthly follow-up visits for a total of one year. At each follow-up, the following assessments will be performed: complete blood count, liver and kidney function tests, bone marrow aspiration, flow cytometric measurement of minimal residual disease (MRD), and/or fusion gene analysis, along with monitoring of other efficacy endpoints and adverse reactions.
Key facts
- Study ID
- NCT07642453
- Run by
- Hematology department of the 920th hospital
- People needed
- 110
- Starts
- 2026-06-01
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of acute myeloid leukemia confirmed according to NCCN guidelines;
- Age 18-75 years;
- Body weight 30-100 kg;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3;
- No significant organ dysfunction (echocardiographic ejection fraction >45%; bilirubin <2 times the upper limit of normal; AST and ALT <3 times the upper limit of normal; serum creatinine <2 times the upper limit of normal);
- No severe infections;
- Study participants voluntarily agree to participate in this clinical trial and sign an informed consent form.
You may not qualify if…
- Patients with other types of diseases;
- Patients with a projected survival of less than 1 month;
- History of prior treatment;
- Severe psychiatric or neurological disorders that impair the ability to provide informed consent and/or report or observe adverse events;
- Other circumstances deemed unsuitable for enrollment by the investigator.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.